U.S. Markets closed

Athenex Shares Are Trading Higher On Positive Oral Paclitaxel Data From Solid Tumor Trial

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Athenex Inc (NASDAQ: ATNX) announced data presentation from a Phase 1 study evaluating encequidar (Oral Paclitaxel) in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in advanced solid malignancies.

  • Paclitaxel is one of the most commonly used chemotherapies.

  • Related Link: Athenex Issues Update On Oral Paclitaxel Application In Metastatic Breast Cancer.

  • Data were presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021.

  • The dose-escalation phase of the study enrolled 21 patients. Activity data were presented on 17 evaluable patients.

  • Four patients had a partial response, ten patients had stable disease, and three had progressive disease.

  • There were ten non-small cell lung cancer (NSCLC) patients enrolled, of which eight were evaluable for response.

  • Four patients achieved a partial response, and four patients achieved stable disease.

  • All the patients had discontinued previous checkpoint inhibitor therapy due to progressive disease.

  • The maximum tolerated dose of the combination was not reached.

  • Price Action: ATNX shares are up 1.77% at $3.45 during the premarket session on the last check Thursday.

  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.